Literature DB >> 15452765

Do costs of varicella justify routine infant vaccination? Pharmacoeconomic and clinical considerations.

M J Postma1, J M Bos, R Welte, R de Groot, W Luytjes, H C Rümke, P Beutels.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15452765     DOI： 10.1007/s10198-003-0201-6

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  20 in total

Review 1.  Antiviral therapies for herpes zoster infections. Are they economically justifiable?

Authors:  K J Smith; M S Roberts
Journal:  Pharmacoeconomics       Date:  2000-08       Impact factor: 4.981

Review 2.  Health economic guidelines--similarities, differences and some implications.

Authors:  J Hjelmgren; F Berggren; F Andersson
Journal:  Value Health       Date:  2001 May-Jun       Impact factor: 5.725

3.  Prevention of chickenpox in reproductive-age women: cost-effectiveness of routine prenatal screening with postpartum vaccination of susceptibles.

Authors:  W J Smith; L A Jackson; D H Watts; T D Koepsell
Journal:  Obstet Gynecol       Date:  1998-10       Impact factor: 7.661

4.  Costs and benefits of routine varicella vaccination in German children.

Authors:  P Beutels; R Clara; G Tormans; E Van Doorslaer; P Van Damme
Journal:  J Infect Dis       Date:  1996-11       Impact factor: 5.226

5.  Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV.

Authors:  M Brisson; W J Edmunds; N J Gay
Journal:  J Med Virol       Date:  2003       Impact factor: 2.327

6.  Cost-effectiveness of routine antenatal varicella screening.

Authors:  J C Glantz; A I Mushlin
Journal:  Obstet Gynecol       Date:  1998-04       Impact factor: 7.661

7.  Risk factors and outcome of varicella-zoster virus pneumonia in pregnant women.

Authors:  James H Harger; Joseph M Ernest; Gary R Thurnau; Atef Moawad; Valerija Momirova; Mark B Landon; Richard Paul; Menachem Miodovnik; Mitchell Dombrowski; Baha Sibai; Peter Van Dorsten
Journal:  J Infect Dis       Date:  2002-01-17       Impact factor: 5.226

8.  The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France.

Authors:  L Coudeville; F Paree; T Lebrun; J Sailly
Journal:  Vaccine       Date:  1999-01       Impact factor: 3.641

9.  The burden of varicella in Germany. Potential risks and economic impact.

Authors:  Kurt Banz; Stefan Wagenpfeil; Albrecht Neiss; Thomas Hammerschmidt; Peter Wutzler
Journal:  Eur J Health Econ       Date:  2004-02

10.  The cost-effectiveness of routine childhood varicella vaccination in Germany.

Authors:  K Banz; S Wagenpfeil; A Neiss; A Goertz; U Staginnus; J Vollmar; P Wutzler
Journal:  Vaccine       Date:  2003-03-07       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.